ArticleFrontiers in cellular and infection microbiology2026
Intelligent
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Malaria remains a major global health burden and motivates fast, reliable in silico prioritization of antimalarial (AM) peptide candidates. Designing such peptides is challenging due to the vast search space, scarce or noisy supervision, and potential out-of-distribution miscalibration of computational scores. Prior pipelines typically rank existing sequences rather than generate new candidates under explicit design constraints with calibrated, risk-aware decision rules. Methods: We propose a constraint-guided generate-then-classify framework. A low-data generator-an optimized variant of CTCM-Neo-proposes de novo sequences within APD3-derived windows for net charge, GRAVY, and Boman index. A frozen, temperature-scaled protein language-model classifier (ConformaX-PEP) outputs calibrated probabilities for predicted antimalarial activity and hemolysis, and a split-conformal gate with risk level α=0.1 converts these scores into accept/reject decisions at fixed operating thresholds Results: On the initial 322-sequence corpus (52 AM, 200 unlabeled, 70 positive-like), a held-out evaluation achieves AUROC ≈0.93, AUPRC ≈0.80, and ECE ≈0.03, indicating strong discrimination with low calibration error prior to external testing. The method outperforms strong baselines in convergence speed and reliability. On 210 previously unseen peptides (80 AM, 130 NM), two independent runs achieve 92.86% and 93.33% accuracy with balanced precision and recall and good calibration. Hyperparameter sweeps reveal broad, stable optima, supporting reproducibility. Template-based docking with GalaxyPepDock is used strictly as a hypothesis-generating structural sanity check and does not constitute evidence of biological binding or efficacy. Discussion: Overall, the framework compresses the search space into a small, risk-bounded set of computationally prioritized candidates and provides a scalable, uncertainty-aware route for downstream experimental follow-up. All results reported here are computational, and antimalarial activity remains to be confirmed experimentally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.